About Remedium Bio
Remedium Bio is a company based in Needham (United States) founded in 2020 by Frank Luppino. Remedium Bio has raised $15 million across 7 funding rounds from investors including MicroVentures, Guindy Alumni Angels and LifeSpan Vision Ventures. Remedium Bio offers products and services including Prometheus Platform, Gene Therapy for Obesity and T2D, and Gene Therapy for Stroke. Remedium Bio operates in a competitive market with competitors including Moderna, BridgeBio, Spark Therapeutics, Alnylam and ATAI, among others.
- Headquarter Needham, United States
- Founders Frank Luppino
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website remedium-bio.com
- Social LinkedIn X YouTube
- Total Equity Funding$15M (USD)
in 7 rounds
- Latest Funding Round$10M (USD), Series A
Aug 2026
- InvestorsMicroVentures
& 9 more
Products & Services of Remedium Bio
Remedium Bio offers a comprehensive portfolio of products and services, including Prometheus Platform, Gene Therapy for Obesity and T2D, and Gene Therapy for Stroke.
Adjustable gene therapy for safe delivery of treatments
Single-injection therapy targeting weight loss and diabetes
Regenerative treatment for ischemic stroke recovery
Apps and channels of Remedium Bio
its YouTube channel Remedium Bio has 8 subscribers and 4 videos.
Videos from Remedium Bio
The most watched videos on Remedium Bio's YouTube channel, Remedium Bio (8 subscribers). Click a video to play it here.
More on Remedium Bio.
Funding Insights of Remedium Bio
Remedium Bio has successfully raised a total of $15M across 7 strategic funding rounds. The most recent funding activity was a Series A round of $10 million completed in August 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $15M
- Total Rounds 7
- Last Round Series A — $10M
- First Round $1.2M
(Apr 2021)
- Investors Count 10
All 7 funding rounds of Remedium Bio with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2026 | $10M | Series A | – | LifeSpan Vision Ventures | |
| May 2026 | $1.5M | Series A | – | – | – |
| Sep 2024 | – | Seed | – | LifeSpan Vision Ventures | – |
| Aug 2023 | $274,966 | Grant | – | – | |
| Aug 2022 | $2.3M | Seed | – | – | |
| Nov 2021 | $4.43M | Debt – Conventional | – | – | – |
| Apr 2021 | $1.2M | Seed | – | – | – |
10 investors in total: 10 institutional.
Investors in Remedium Bio
Remedium Bio has secured backing from 10 investors, including venture fund and institutional investors. Prominent investors backing the company include MicroVentures, Guindy Alumni Angels and LifeSpan Vision Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
- | – | lifespanvisionventures.com | - | |
Sherwood Ventures is engaged in management consulting with equity stakes. | – | sherwoodv.com | Toronto, Canada | |
- | – | longevitytech.fund | - | |
Early-stage startups are supported with funding and mentorship by Angel Star Ventures. | – | angelstarventures.com | Chadds Ford, USA | |
- | – | apishealthangels.com | - | |
A network focused on financing innovation and promoting entrepreneurship among alumni. | 2022 | guindyangels.com | Chennai, India | |
A government-backed foundation providing seed-stage investments to support small businesses. | 1950 | nsf.gov | Arlington, United States | |
- | – | primomedicalgroup.com | - | |
Equity crowdfunding is provided for startups and private markets. | 2009 | microventures.com | Austin, United States | |
- | – | lilly.com | - |
Investor details for Remedium Bio
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Remedium Bio
3 people are tracked at Remedium Bio (2 in leadership, 1 in board & advisors).
| Name | Role | Group |
|---|---|---|
Frank Luppino | Founder & CEO | Leadership |
Alex Goraltchouk | Chief Operating Officer | Leadership |
Richard Hague | Board Member | Board & advisors |
Complete people profiles for Remedium Bio
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Remedium Bio
3 dated milestones of Remedium Bio across 6 years, from founding to its latest funding, stage changes and deals.
- Founded Remedium Bio is founded.
- Funding First funding round of $1.2M.
- Funding Latest funding round, Series A, of $10.0M.
Competitors of Remedium Bio
Remedium Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, BridgeBio, Spark Therapeutics, Alnylam and ATAI, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| bridgebio.com | 2015 | Palo Alto, United States | $434.2M | – | Therapeutics for genetic diseases are developed through targeted interventions. | |
| sparktx.com | 2013 | Philadelphia, United States | $82.8M | 822 | Gene therapies for rare diseases including retinal dystrophies are developed. | |
| alnylam.com | 2002 | Cambridge, United States | $17M | 2,100 | RNA interference-based therapeutics are developed for multiple disorders. | |
| atai.life | 2018 | Munich, Germany | $386.67M | – | A biopharmaceutical company accelerating innovative mental health treatments. | |
| insitro.com | 2018 | San Francisco, United States | $643.21M | 257 | An AI-enabled platform is developed for infectious disease treatment. | |
| horizontherapeutics.com | 2008 | Dublin, Ireland | $61.78M | – | Developer of drugs for treating rare and autoimmune diseases | |
| ultragenyx.com | 2010 | Novato, United States | $135.1M | 837 | Therapeutics for rare and ultra-rare metabolic diseases are developed. | |
| forgebiologics.com | 2020 | Columbus, United States | $250M | 118 | Gene therapies for rare diseases are developed to treat patients. | |
| argenx.com | 2008 | Ghent, Belgium | $61.9M | 355 | Antibody-based drugs are developed for autoimmune diseases and cancer treatment. |
Detailed competitors of Remedium Bio
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Remedium Bio
The website of Remedium Bio (remedium-bio.com) receives about 1.5K visits a month.
- Monthly visits1.5K
▲ 5.7% vs previous month
Latest news on Remedium Bio
Complete news archive for Remedium Bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Remedium Bio
10 companies that operate in the same segment as Remedium Bio (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 265 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Remedium Bio
Remedium Bio was founded in 2020 and raised its 1st funding round 1 year after it was founded.
Remedium Bio is headquartered in Needham, United States. It is registered at Needham, Massachusetts, United States.
Frank Luppino is the current CEO of Remedium Bio. They have also founded this company.
Remedium Bio is a funded company, having raised a total of $15M across 7 funding rounds to date. The company's 1st funding round was a Seed of $1.2M, raised on Apr 2021.
Remedium Bio was founded in 2020 and is based in Needham, United States. Gene therapies are developed for a range of diseases, particularly immune and age-related conditions. The pipeline encompasses RMD 1101 for rheumatology, RMD 1202 for endocrinology, RMD 1501 for neurology, and RMD 1201 for Type-1 diabetes. Operations are conducted in the biotechnology sector, with emphasis on therapeutic advancements for these areas.
Remedium Bio's top competitors include Moderna, Spark Therapeutics and BridgeBio.
Remedium Bio offers Prometheus Platform, Gene Therapy for Obesity and T2D, and Gene Therapy for Stroke.
Remedium Bio has 10 investors. Key investors include MicroVentures, Guindy Alumni Angels, LifeSpan Vision Ventures, National Science Foundation, and Sherwood Ventures.